StockNews.AI
ANRO
StockNews.AI
13 hrs

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

1. Deadline approaching for investors in Alto Neuroscience's securities lawsuit. 2. Investors who lost over $100,000 are urged to act by September 19, 2025. 3. Lawsuit alleges misleading statements about ALTO-100's effectiveness and company prospects. 4. Plaintiffs claim IPO documents overstated ALTO-100's clinical and regulatory potential. 5. Investors encouraged to contact Shareholders Foundation for assistance.

8m saved
Insight
Article

FAQ

Why Bearish?

Legal challenges can undermine investor confidence, impacting stock price. Previous examples show drops in stock value during litigation periods.

How important is it?

This article highlights legal risks that could deter investments, affecting stock performance directly.

Why Short Term?

Current legal developments and deadlines create immediate concerns for investors. Short-term volatility often follows news of lawsuits.

Related Companies

SAN DIEGO, Aug. 18, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Alto Neuroscience, Inc. (NYSE:ANRO).

Investors who purchased in excess of $100,000 in shares of Alto Neuroscience, Inc. (NYSE:ANRO) between February 2, 2024 and October 22, 2024, have certain options and there are short and strict deadlines running. Deadline: September19, 2025. NYSE: ANRO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On July 21, 2025, a NYSE: ANRO investor filed a lawsuit over alleged securities laws violations by Alto Neuroscience, Inc. The plaintiff alleges that the Offering Documents that were filed in connection with the Company's IPO conducted on or about February 2, 2024 and that certain statements made by the defendants between February 2, 2024 and October 22, 2024 were false and/or misleading statements and/or failed to disclose that ALTO-100 was less effective in treating MDD than Defendants had led investors to believe, that accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated, that as a result, Alto's business and/or financial prospects were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased Alto Neuroscience, Inc. (NYSE:ANRO) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc. 

Michael Daniels 

+1 (858) 779-1554 

mail@shareholdersfoundation.com 

3111 Camino Del Rio North 

Suite 423 

San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-deadline-investors-who-purchased-over-100-000-worth-of-shares-of-alto-neuroscience-inc-nyse-anro-between-feb-and-oct-2024-should-contact-the-shareholders-foundation-302531872.html

SOURCE Shareholders Foundation, Inc.

Related News